Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
Key Highlights
- ➤$9.0 million cash and equivalents expected to fund operations into Q2 2028
- ➤Q3 net loss narrowed to $1.1 million, or $0.05 per share
- ➤SGX945 showed biological activity and was generally safe in Phase 2a study
- ➤Soligenix is evaluating partnerships, licensing, mergers and acquisitions, grants and contracts
- ➤Research and development expenses fell to $0.4 million from $1.6 million
Expert Statements
Christopher J. Schaber, President and Chief Executive Officer of Soligenix
“We are continuing to pursue all strategic options to maximize stockholder value, including within our own rare disease portfolio.”
Christopher J. Schaber, President and Chief Executive Officer of Soligenix
“This includes advancement of SGX945 (dusquetide) for Behçet's disease, which showed encouraging signs of biological activity and was generally safe and well-tolerated in a small, open-label Phase 2a proof-of-concept study, as well as our ThermoVax® heat-stable vaccine platform”
Christopher J. Schaber, President and Chief Executive Officer of Soligenix
“With approximately $9.0 million in cash and cash equivalents as of September 30, 2026, which we believe is sufficient to fund our current operating plan into the second quarter of 2028, we are evaluating a number of potential opportunities, including but not limited to partnership, licensing, merger and acquisition, government grants and contracts, while advancing our existing pipeline.”
Christopher J. Schaber, President and Chief Executive Officer of Soligenix
“Maintaining our Nasdaq listing is also an important strategic asset that supports these efforts by preserving access to the public capital markets, enhancing our attractiveness to potential strategic partners and acquirers, and providing additional flexibility as we evaluate these opportunities.”
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results PR Newswire
PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.